Plasma Fractionation Market Business Insights
As reported by SNS Insider, the global Plasma Fractionation Market was valued at USD 33.47 billion in 2023 and is projected to reach USD 63.82 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.4% over the forecast period from 2024 to 2031.
Market Overview
Plasma fractionation is a process used to separate and purify various components of human plasma, including clotting factors, immunoglobulins, and albumin. These components are essential for treating a range of medical conditions, such as bleeding disorders, immune deficiencies, and liver diseases. The market for plasma fractionation is expanding due to the rising prevalence of hemophilia, increasing demand for immunoglobulins, and advancements in fractionation technologies that improve product yield and safety.
Get Free Sample Copy of Report: https://www.snsinsider.com/sample-request/2992
Key Players
- CSL Limited
- Grifols S.A.
- Takeda Pharmaceutical Company Limited
- Octapharma AG
- Shire (now part of Takeda)
- BioLife Plasma Services
- Kedrion Biopharma
- LFB Group
- Shanghai Raas Blood Products Co., Ltd.
- Hualan Biological Engineering Inc.
KEY MARKET SEGMENTATION
By Product Type
- Immunoglobulins
- Clotting Factors
- Albumin
- Others
By Application
- Hemophilia
- Immune Deficiencies
- Liver Diseases
- Other Therapeutic Areas
By End Users
- Hospitals
- Blood Banks
- Research Institutes
- Others
Market Dynamics
- Increasing Prevalence of Hemophilia: The rising number of hemophilia cases globally is driving the demand for plasma-derived clotting factors. Advances in treatment options are contributing to the growth of the plasma fractionation market.
- Growing Demand for Immunoglobulins: Immunoglobulins are used to treat a variety of immune disorders and are in high demand due to their critical role in managing autoimmune diseases and infections.
- Technological Advancements: Innovations in plasma fractionation technology, such as improved separation techniques and enhanced product safety measures, are boosting market growth. These advancements lead to higher yields and better patient outcomes.
- Expansion of Plasma Collection Networks: The growth of plasma collection centers and increased public awareness about plasma donation are supporting market expansion and ensuring a steady supply of plasma for fractionation.
Regional Insights
- North America: Leads the market due to the presence of major pharmaceutical companies, advanced healthcare infrastructure, and a high prevalence of plasma-derived therapies.
- Europe: Shows substantial growth potential, driven by increasing investments in healthcare and rising demand for plasma-derived products.
- Asia-Pacific: Expected to experience rapid growth due to expanding healthcare infrastructure, a growing patient population, and increasing awareness of plasma fractionation benefits.
Key Players
- CSL Limited
- Grifols S.A.
- Takeda Pharmaceutical Company Limited
- Octapharma AG
- Shire (now part of Takeda)
Future Outlook
The Plasma Fractionation Market is poised for significant growth, driven by the increasing prevalence of blood disorders, rising demand for plasma-derived therapies, and technological advancements in fractionation processes. Continued investment in research and development is expected to further enhance market expansion and improve treatment options.
Table of Contents
- Introduction
- Research Methodology
- Market Dynamics
- Impact Analysis
- Value Chain Analysis
- Porter’s 5 forces model
- PEST Analysis
- Global Human Insulin Market Segmentation, By Product
- Plasma Fractionation Market Segmentation, By Application
- Plasma Fractionation Market Segmentation By End User
- Regional Analysis
- Company profile
- Competitive Landscape
- Used Cases and Best Practices
- Conclusion
Related Reports
Compression Therapy Market Challenges
Multiple Myeloma Market Challenges
Foley Catheter Market Challenges
Contact Us:
Akash Anand – Head of Business Development & Strategy
[email protected]
Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)
Website: https://www.snsinsider.com/
